# Research on Correlations of lncRNA ST7-AS1 with Progression and Therapeutic Targets of Esophageal Cancer

## TL;DR

This study explores how the lncRNA ST7-AS1 contributes to esophageal cancer progression and identifies its potential as a therapeutic target.

## Contribution

The study reveals that ST7-AS1 acts as a miR-4262 sponge, offering a new therapeutic target for esophageal cancer.

## Key findings

- ST7-AS1 is overexpressed in esophageal cancer tissues and correlates with shorter patient survival.
- Silencing ST7-AS1 reduces cancer cell proliferation, migration, and invasion.
- ST7-AS1 functions as a miR-4262 sponge, and miR-4262 inhibition reverses the effects of ST7-AS1 knockdown.

## Abstract

Esophageal cancer is a highly prevalent gastrointestinal tumor in China, resulting in a significant number of deaths annually. In this paper, we investigated the regulatory role and therapeutic potential of aberrant ST7-AS1 expression in esophageal cancer.

The presence of ST7-AS1 in 125 esophageal cancer tissues was identified through RT-qPCR assays. The application of Kaplan-Meier to evaluate survival rates in patients with esophageal cancer. Cell activity was assessed by both CCK-8 and Transwell assays. The luciferase activity assay verified the association of ST7-AS1 with miR-4262.

ST7-AS1 expression in esophageal cancer was noticeably overexpressed compared to the control group. Patients with upregulated ST7-AS1 had shorter survival rates. Silencing ST7-AS1 reduced the proliferation level of esophageal cancer cells, as did the migration and invasion levels. Mechanistically, ST7-AS1 acted as a sponge for miR-4262, affecting the progression of esophageal cancer. This was negatively correlated with ST7-AS1. Moreover, the miR-4262 inhibitor negated the inhibitory effect of silencing ST7-AS1 on cells.

Knockdown of ST7-AS1 may alleviate tumor progression by targeting miR-4262, indicating that ST7-AS1 is anticipated to serve as a therapeutic biomarker for patients with esophageal cancer.